Invenomic Capital Management has completely exited its position in Haemonetics Corporation (HAE), selling 498,317 shares valued at $24.29 million, according to a recent SEC filing. This move eliminates Haemonetics from Invenomic’s portfolio, which previously represented 1.2% of its assets under management.
The decision to divest comes amid a challenging period for Haemonetics, whose shares have dropped 9% over the past year, significantly lagging behind the S&P 500’s 16% gain. Despite a recent surge of nearly 70% following better-than-expected earnings, the company has since faced a 27% decline this year, driven by revenue contractions and a complex business landscape marked by divestitures and shifting product dynamics. While profitability metrics have improved, this tension between growth and efficiency may have prompted Invenomic’s strategic exit.
For investors, this development underscores the evolving narrative around Haemonetics, suggesting a shift from a growth-oriented investment to a more nuanced evaluation of stability and profitability. For a deeper dive into the implications of this transaction, I recommend exploring the full article.
Source: fool.com